Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
77.1M
-
Number of holders
-
121
-
Total 13F shares, excl. options
-
40.4M
-
Shares change
-
+935K
-
Total reported value, excl. options
-
$1.17B
-
Value change
-
+$25.9M
-
Number of buys
-
60
-
Number of sells
-
-46
-
Price
-
$28.95
Significant Holders of Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) as of Q4 2021
134 filings reported holding NRIX - Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2021.
Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) has 121 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 40.4M shares
of 77.1M outstanding shares and own 52.4% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (4.87M shares), Redmile Group, LLC (2.96M shares), BlackRock Inc. (2.55M shares), BAKER BROS. ADVISORS LP (2.45M shares), TRV GP III, LLC (2.42M shares), VANGUARD GROUP INC (1.99M shares), EVENTIDE ASSET MANAGEMENT, LLC (1.87M shares), STATE STREET CORP (1.56M shares), Bain Capital Life Sciences Investors, LLC (1.28M shares), and BOXER CAPITAL, LLC (1.22M shares).
This table shows the top 121 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.